Vitiligo Linked to Elevated Risk of Social Phobia, Anxiety vs General Population

Individuals with vitiligo face significantly higher rates of social phobia and anxiety disorders compared with the general population, according to a retrospective matched cohort study published in BMJ Open.¹

The findings add new population-level evidence to a growing body of literature documenting the psychosocial toll of the skin condition.

“Persons with vitiligo and those with other chronic skin conditions such as atopic dermatitis (AD) or psoriasis often suffer from various comorbidities,” the authors explained. “Numerous published studies also point to an increased risk of mental health disorders (MHDs) such as depression, insomnia, anxiety, stress, and adjustment disorders, especially in persons with vitiligo and the entire group of people with chronic skin conditions.”^2,3

The study analyzed a 40% anonymized sample of German statutory health insurance (SHI) claims data covering nearly 2.9 million insured individuals between 2016 and 2020.¹ In 2020, 4631 cases of vitiligo were diagnosed, corresponding to an estimated prevalence of 0.19%—or roughly 148,000 individuals across Germany.

Across all case definitions, affective disorders and neurotic, stress-related, and somatoform disorders were the most prevalent mental health comorbidities. Depressive episodes were the most common diagnosis, with prevalence ranging from 8.9% to 19.2% depending on the stringency of the case definition applied. Somatoform disorders followed closely, ranging from 5.3% to 17.9%.

“Affective disorders, particularly depressive episodes and recurrent depressive disorders, exhibited the highest prevalence across all case definitions, proving them to be diagnostically robust entities in routine data,” the authors wrote.

Compared with those without vitiligo, social phobia demonstrated the strongest association, with relative risks ranging from 2.10 to 2.81 across definitions. Phobic and anxiety disorders more broadly showed consistently increased relative risks between 1.64 and 1.93 across all definitions—findings the authors characterized as robust given their stability under increasingly strict diagnostic criteria.

Mental Health Comorbidities With Vitiligo, Atopic Dermatitis, and Psoriasis

Another notable finding was how the mental health comorbidity profile of vitiligo compared with other skin conditions. Few significant differences were seen between vitiligo and atopic dermatitis, suggesting a similar psychosocial burden between the conditions.

However, those with vitiligo showed meaningfully higher risks for obsessive-compulsive personality disorder, hyperkinetic disorders, and emotional disorders of childhood compared with individuals with psoriasis—differences that held across multiple case definitions.

“Because of its high visibility, vitiligo can be associated with social stigma, discrimination, and psychological distress even in childhood and adolescence,” the authors wrote. “Conversely, psoriasis can often be hidden by clothing. This visibility could lead to a comparatively higher psychosocial burden in persons with vitiligo compared with persons with psoriasis, even in early childhood.”

The study also developed 3 expert-informed case definitions with increasing diagnostic specificity—a framework designed to address known limitations of claims-based psychiatric diagnoses. The approach revealed that prevalence estimates for certain conditions, such as adjustment disorders, were highly sensitive to case definition, while others, like recurrent depressive disorder, remained comparatively stable.

The authors acknowledged that claims data inherently undercount untreated mental health conditions, and future research linking administrative data with clinical records would strengthen prevalence estimates. Still, they concluded that the tiered validation approach provides a replicable model for psychiatric epidemiology research using routine SHI data.

“These findings highlight the heterogeneity of psychosocial comorbidity in dermatological diseases and caution against generalizing psychological distress across different clinical presentations,” the authors concluded.

References

1. Klinger T, Augustin M, Leicht G, Moritz S, Hagenström K. Prevalence and comparative risk of mental health disorders in persons with vitiligo: a retrospective matched cohort study using claims data with expert-informed case validation. BMJ Open. Published online March 4, 2026. doi:10.1136/bmjopen-2025-106687

2. Eleftheriadou V, Delattre C, Chetty-Mhlanga S, et al. Burden of disease and treatment patterns in patients with vitiligo: findings from a national longitudinal retrospective study in the UK. Br J Dermatol. 2024;191(2):216-224. doi:10.1093/bjd/ljae133

3. Fabrazzo M, Cipolla S, Signoriello S, et al. A systematic review on shared biological mechanisms of depression and anxiety in comorbidity with psoriasis, atopic dermatitis, and hidradenitis suppurativa. Eur Psychiatry. 2021;64(1):e71. doi:10.1192/j.eurpsy.2021.2249